References
Strout MP, Marcucci G, Bloomfield CD, Caligiuri MA . The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci USA 1998; 95: 2390–2395.
Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998; 58: 55–59.
Dohner K, Tobis K, Ulrich R, Frohling S, Benner A, Schlenk RF et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002; 20: 3254–3261.
Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D, Haferlach T et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000; 14: 796–804.
Whitman SP, Ruppert AS, Marcucci G, Mrozek K, Paschka P, Langer C et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 2007; 109: 5164–5167.
Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 2008; 112: 2013–2016.
Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood 2012; 120: 1130–1136.
Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 2012; 120: 2466–2474.
Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97: 1172–1179.
Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25: 3884–3891.
Lu Q, Wang DS, Chen CS, Hu YD . Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005; 48: 5530–5535.
Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5: e10941.
Mims A, AR Walker, Huang X, Sun J, Wang H, Santhanam R et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia 2012; 27: 871–878.
Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010; 107: 7473–7478.
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271–3279.
Acknowledgements
We thank The Ohio State University Comprehensive Cancer Center’s Shared Resources: Biostatistics, Nucleic Acid, Comparative Pathology and Mouse Phenotyping and Analytical Cytometry. This work was supported in part by National Cancer Institute, Bethesda, MD, USA, grants: to MAC (CA089341; CA009338), to GM (CA102031), to MAC and GM (CA140158), to NAZ (T32 GM12453), and to KMB (T32 CA009338). We also thank the Thomas J. Bardos Science Education Award (RFS), the American Society of Hematology Trainee Research Award (RFS), the OSU College of Medicine Fellowship (NAZ), Pelotonia Fellowships (NAZ, RFS, and AMD), Wells Family Fellowship (JSN and DLB) and the American Society of Hematology Minority Medical Student Award Program (MN).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
CSC is the inventor of AR42, and has received royalty payments from Arno Therapeutics per the licensing agreement of AR42 between the Ohio State University Research Foundation and Arno Therapeutics. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Bernot, K., Siebenaler, R., Whitman, S. et al. Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. Leukemia 27, 2379–2382 (2013). https://doi.org/10.1038/leu.2013.147
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.147
- Springer Nature Limited
This article is cited by
-
Origins of aberrant DNA methylation in acute myeloid leukemia
Leukemia (2014)